文献速递肝病消化道肿瘤与早癌

IMbrave050 更新数据:高危肝细胞癌辅助阿替利珠单抗联合贝伐珠单抗

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2026-01-22

IMbrave050 研究纳入根治性切除或消融后高复发风险的肝细胞癌患者,随机接受阿替利珠单抗联合贝伐珠单抗或主动监测。预设期中分析时无复发生存期获益显著(HR 0.72),但更新分析中该获益未维持(HR 0.90),总生存数据仍不成熟。结论不支持该联合方案用于辅助治疗。

要点

  • 更新分析中无复发生存期获益未维持,HR 0.90(95%CI 0.72-1.12)。
  • 第二次期中分析总生存数据仍不成熟,HR 1.26(95%CI 0.85-1.87)。
  • 安全性谱与首次分析一致,但获益-风险比不支持辅助治疗。

核心结论

  • 更新分析显示阿替利珠单抗联合贝伐珠单抗对比主动监测的初始无复发生存期获益未维持,总生存数据仍不成熟,获益-风险比不支持其作为辅助治疗。

研究设计与样本

  • IMbrave050 为随机对照试验,纳入根治性切除或消融后高复发风险的肝细胞癌患者,按1:1随机接受阿替利珠单抗1200mg联合贝伐珠单抗15mg/kg静脉每3周(17周期)或主动监测1年。

主要发现

  • 更新分析中无复发生存期风险比为0.90(95%CI 0.72-1.12)。
  • 第二次期中分析总生存风险比为1.26(95%CI 0.85-1.87),数据仍不成熟。
  • 无复发生存期和总生存结果在临床相关亚组中一致。
  • 更新安全性数据与主要分析一致。

临床怎么用

  • 当前证据不支持阿替利珠单抗联合贝伐珠单抗用于肝细胞癌辅助治疗。
  • 亚组分析提示部分患者可能获益,但需进一步前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: At the pre-specified interim analysis (IA; median follow-up, 17.4 months), IMbrave050 met its primary endpoint of improved independent review facility (IRF)-assessed recurrence-free survival (RFS) in patients with high-risk hepatocellular carcinoma (HCC). The RFS hazard ratio (HR) for atezolizumab plus bevacizumab vs. active surveillance was 0.72 (adjusted 95% CI 0.53-0.98; p = 0.012), and overall survival (OS) data were immature. Here, we report an updated post hoc analysis of RFS and the second IA of OS, along with additional data. METHODS: IMbrave050 enrolled patients with HCC who had high recurrence risk following curative-intent resection or ablation. Patients were randomized 1:1 to receive atezolizumab 1,200 mg plus bevacizumab 15 mg/kg intravenously every 3 weeks (17 cycles) or active surveillance for 1 year; patients were eligible to cross over to atezolizumab plus bevacizumab following IRF-assessed recurrence. Stratification factors included geographic region and a composite factor comprising the number of high-risk features, curative procedure, and use of optional adjuvant transarterial chemoembolization (one cycle) post-resection. Secondary endpoints included OS and safety. RESULTS: In the updated analysis, RFS HR was 0.90 (95% CI 0.72-1.12). At the second IA, OS data remained immature (HR 1.26; 95% CI 0.85-1.87). RFS and OS results were consistent across clinically relevant subgroups. Updated safety data were consistent with the primary analysis. CONCLUSIONS: In this updated analysis, the initial RFS benefit seen with atezolizumab plus bevacizumab vs. active surveillance was not sustained and OS data remained immature. The safety profile of atezolizumab plus bevacizumab remained manageable and consistent with that of each agent and the underlying disease. Overall, the benefit-risk profile does not support atezolizumab plus bevacizumab as adjuvant therapy. IMPACT AND IMPLICATIONS: Based on results from the IMbrave150 trial, atezolizumab in combination with bevacizumab is the standard-of-care first-line treatment for unresectable hepatocellular carcinoma (HCC), prompting interest in investigating the combination in earlier treatment settings. IMbrave050 was the first immunotherapy study to report data in the adjuvant setting for HCC, where an early recurrence-free survival benefit was observed at the pre-specified interim analysis but not maintained with longer follow-up; overall survival data remained immature. The updated results of IMbrave050 do not support the use of atezolizumab plus bevacizumab in the adjuvant setting. However, subgroup analyses suggest a potential benefit in select patients, warranting further prospective evaluation. Effective perioperative or adjuvant treatment remains a major unmet need for patients with HCC given the high rate of early post-operative relapse. CLINICAL TRIAL NUMBER: NCT04102098.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yopp A, Chen M, Cheng AL, et al. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol. 2026. PMID: 41580093. doi:10.1016/j.jhep.2026.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。